Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients

Authors not listed

Severance Hospital · 2025

Abstract

In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary endpoint along with progression-free survival, toxicity, quality of life, and prognostic biomarkers.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-06 MST

Cite this

APA
Anonymous. (2025). Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients. <em>Severance Hospital</em>. https://clinicaltrials.gov/study/NCT05439278
Vancouver
Anonymous. Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients. Severance Hospital. 2025.
BibTeX
@misc{anon2025Random, title = {Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients}, author = {Anonymous}, journal = {Severance Hospital}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings